ClinVar Miner

Submissions for variant NM_001079866.2(BCS1L):c.399del (p.Glu133fs)

dbSNP: rs751484879
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Laboratory Services, Illumina RCV000778594 SCV000914901 uncertain significance BCS1L-related disorder 2017-08-22 criteria provided, single submitter clinical testing The BCS1L c.399delA (p.Glu133AspfsTer25) variant has been reported in one study and is found in one individual with complex III deficiency in a compound heterozygous state with a missense variant. The variant was also present in the unaffected mother in a heterozygous state (Tegelberg et al. 2017). Control data are unavailable for the p.Glu133AspfsTer25 variant, which is reported at a frequency of 0.00036 in the European American population of the Exome Sequencing Project. Based on the limited evidence, the p.Glu133AspfsTer25 variant is classified as a variant of unknown significance but suspicious for pathogenicity for BCS1L-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000801063 SCV000940819 pathogenic not provided 2023-12-20 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu133Aspfs*25) in the BCS1L gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCS1L are known to be pathogenic (PMID: 12215968, 17314340, 19162478, 19508421, 22277166, 25895478). This variant is present in population databases (rs751484879, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BCS1L-related conditions. ClinVar contains an entry for this variant (Variation ID: 631845). For these reasons, this variant has been classified as Pathogenic.
Revvity Omics, Revvity RCV000801063 SCV003821650 likely pathogenic not provided 2022-04-01 criteria provided, single submitter clinical testing
Baylor Genetics RCV003472307 SCV004210799 pathogenic Pili torti-deafness syndrome 2023-08-25 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001825516 SCV005039956 pathogenic GRACILE syndrome 2024-03-08 criteria provided, single submitter clinical testing Variant summary: BCS1L c.399delA (p.Glu133AspfsX25) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 7.6e-05 in 251496 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in BCS1L causing GRACILE Syndrome (7.6e-05 vs 0.00047), allowing no conclusion about variant significance. c.399delA has been reported in the literature in individuals affected with GRACILE Syndrome. These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. ClinVar contains an entry for this variant (Variation ID: 631845). Based on the evidence outlined above, the variant was classified as pathogenic.
Natera, Inc. RCV001825516 SCV002076349 pathogenic GRACILE syndrome 2020-12-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.